The scramble to research the novel coronavirus has exposed weaknesses in the vetting of healthcare data being supplied by a growing number of U.S. firms, a flaw that forced two of the most respected medical journals to pull studies last week.
FILE PHOTO: The ultrastructural morphology exhibited by the 2019 Novel Coronavirus , which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention in Atlanta, Georgia, U.S. January 29, 2020. Alissa Eckert, MS; Dan Higgins, MAM/CDC/Handout via REUTERS/File Photo
“Whenever you don’t know where data comes from, and precisely how it was managed, then the number of incorrect conclusions you can draw is large,” said Kenneth Mandl, director of the Computational Health Informatics Program at Boston Children’s Hospital. “The field is young enough that those best practices may not be well established across the scientific community.”
The retractions “are great examples of why science needs more of a ‘In God We Trust, everyone else needs to show their data’ approach,” said Ivan Oransky, vice president of editorial at Medscape and co-founder of the Retraction Watch blog. The U.S. Food and Drug Administration now allows data gathered outside of clinical trials to be considered in its reviews of new drugs, providing another boost to the healthcare analytics industry.It is not clear how Surgisphere accessed the data used in the two studies. Surgisphere did not return requests for comment.
A spokesman for Brigham and Women’s Hospital said its data oversight mechanisms “were not applicable” to the Lancet and NEJM studies, adding it only provides “support, guidance and oversight on all agreements that involve the use of our institutional resources, including our patient data.” “We are reviewing our procedures, including how we assess research analyzing large datasets based on electronic medical record data,” said NEJM spokeswoman Jennifer Zeis.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
The Office Elevator In COVID-19 Times: Experts Weigh In On Safer Ups And DownsExperts stress that those riding elevators should wear masks, stay in your corner, face the wall and use items such as disposable tissues or toothpicks to touch the buttons. Also, use hand sanitizer frequently.
続きを読む »
Jacinda Ardern 'did a little dance' for New Zealand's COVID-19 success - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
続きを読む »
Could Heartburn Med Pepcid Ease COVID-19 Symptoms?Famotidine, sold under the brand name Pepcid, appeared to improve symptoms in a group of 10 patients diagnosed with COVID-19, researchers reported online June 4 in the journal Gut.
続きを読む »
These 13 Fashion And Beauty Brands Navigated COVID-19 By Giving BackThe unchartered territory the world faced as a result of COVID-19 has shed light on many industries, especially fashion and beauty. From Uoma Beauty and Cult Gaia, to The Honey Pot and Tribe Kelley, get inspired by the words and actions of these 13 fashion and beauty brands.
続きを読む »
University of Washington forecasts 145,000 U.S. COVID-19 deaths by AugustUniversity of Washington researchers estimated on Monday that 145,728 people could die of COVID-19 in the United States by August, raising their grim forecast by more than 5,000 fatalities in a matter of days.
続きを読む »
Nearly 600 US health care workers have died of COVID-19
続きを読む »